Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 110 of 110 entries
Sorted by: Best Match Show Resources per page
Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers.

Carcinogenesis

Donnelly LL, Hogan TC, Lenahan SM, Nandagopal G, Eaton JG, Lebeau MA, McCann CL, Sarausky HM, Hampel KJ, Armstrong JD, Cameron MP, Sidiropoulos N, Deming P, Seward DJ.
PMID: 34849607
Carcinogenesis. 2021 Dec 31;42(12):1428-1438. doi: 10.1093/carcin/bgab104.

Serine/Threonine Kinase 11 (STK11) encodes an important tumor suppressor that is frequently mutated in lung adenocarcinoma. Clinical studies have shown that mutations in STK11 resulting in loss of function correlate with resistance to anti-PD-1 monoclonal antibody therapy in KRAS-driven...

Cite
Donnelly LL, Hogan TC, Lenahan SM, et al. Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers. Carcinogenesis. 2021;42(12):1428-1438doi: 10.1093/carcin/bgab104.
Donnelly, L. L., Hogan, T. C., Lenahan, S. M., Nandagopal, G., Eaton, J. G., Lebeau, M. A., McCann, C. L., Sarausky, H. M., Hampel, K. J., Armstrong, J. D., Cameron, M. P., Sidiropoulos, N., Deming, P., & Seward, D. J. (2021). Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers. Carcinogenesis, 42(12), 1428-1438. https://doi.org/10.1093/carcin/bgab104
Donnelly, Liam L, et al. "Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers." Carcinogenesis vol. 42,12 (2021): 1428-1438. doi: https://doi.org/10.1093/carcin/bgab104
Donnelly LL, Hogan TC, Lenahan SM, Nandagopal G, Eaton JG, Lebeau MA, McCann CL, Sarausky HM, Hampel KJ, Armstrong JD, Cameron MP, Sidiropoulos N, Deming P, Seward DJ. Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers. Carcinogenesis. 2021 Dec 31;42(12):1428-1438. doi: 10.1093/carcin/bgab104. PMID: 34849607.
Copy Download .nbib Format: NLM
Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Miao YR, Thakkar KN, Qian J, Kariolis MS, Huang W, Nandagopal S, Yang TTC, Diep AN, Cherf GM, Xu Y, Moon EJ, Xiao Y, Alemany H, Li T, Yu W, Wei B, Rankin EB, Giaccia AJ.
PMID: 34011561
Clin Cancer Res. 2021 Aug 01;27(15):4435-4448. doi: 10.1158/1078-0432.CCR-20-0482. Epub 2021 May 19.

PURPOSE: Ovarian cancer represents a major clinical hurdle for immune checkpoint blockade (ICB), with reported low patient response rates. We found that the immune checkpoint ligand PD-L2 is robustly expressed in patient samples of ovarian cancers and other malignancies...

Cite
Miao YR, Thakkar KN, Qian J, et al. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clin Cancer Res. 2021;27(15):4435-4448doi: 10.1158/1078-0432.CCR-20-0482.
Miao, Y. R., Thakkar, K. N., Qian, J., Kariolis, M. S., Huang, W., Nandagopal, S., Yang, T. T. C., Diep, A. N., Cherf, G. M., Xu, Y., Moon, E. J., Xiao, Y., Alemany, H., Li, T., Yu, W., Wei, B., Rankin, E. B., & Giaccia, A. J. (2021). Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4435-4448. https://doi.org/10.1158/1078-0432.CCR-20-0482
Miao, Yu Rebecca, et al. "Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4435-4448. doi: https://doi.org/10.1158/1078-0432.CCR-20-0482
Miao YR, Thakkar KN, Qian J, Kariolis MS, Huang W, Nandagopal S, Yang TTC, Diep AN, Cherf GM, Xu Y, Moon EJ, Xiao Y, Alemany H, Li T, Yu W, Wei B, Rankin EB, Giaccia AJ. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clin Cancer Res. 2021 Aug 01;27(15):4435-4448. doi: 10.1158/1078-0432.CCR-20-0482. Epub 2021 May 19. PMID: 34011561; PMCID: PMC8338886.
Copy Download .nbib Format: NLM
Showing 109 to 110 of 110 entries